Publication:
PNI as a potential add-on biomarker to improve the IMDC intermediate prognostic score

Simple item page
dc.contributor.authorBAYOĞLU, İBRAHİM VEDAT
dc.contributor.authorSEVER, NADİYE
dc.contributor.authorYAŞAR, ALPER
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorSARI, MURAT
dc.contributor.authorKÖSTEK, OSMAN
dc.contributor.authorsBAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., Yaşar A., ARIKAN R., Işık S., Hacıoğlu M. B., et al.
dc.date.accessioned2023-10-30T06:50:36Z
dc.date.available2023-10-30T06:50:36Z
dc.date.issued2023-10-01
dc.description.abstractIntroduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan–Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.
dc.identifier.citationBAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., Yaşar A., ARIKAN R., Işık S., Hacıoğlu M. B., et al., "PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score", Journal of Clinical Medicine, cilt.12, sa.19, 2023
dc.identifier.doi10.3390/jcm12196420
dc.identifier.issn2077-0383
dc.identifier.issue19
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/3b0a0ef3-dcc4-4583-9ec6-bb8bc5830c71/file
dc.identifier.urihttps://hdl.handle.net/11424/294482
dc.identifier.volume12
dc.language.isoeng
dc.relation.ispartofJournal of Clinical Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectGenel Tıp
dc.subjectGeneral Medicine
dc.subjectadjusted PNI-IMDC model
dc.subjectIMDC model
dc.subjectmetastatic RCC
dc.subjectPNI
dc.subjectprognosis
dc.titlePNI as a potential add-on biomarker to improve the IMDC intermediate prognostic score
dc.typearticle
dspace.entity.typePublication
local.avesis.id3b0a0ef3-dcc4-4583-9ec6-bb8bc5830c71
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicationd4f139e7-cf36-415c-a82e-a9c7956ecede
relation.isAuthorOfPublication6b4118fa-7c40-4624-8d36-2f74546b0e2c
relation.isAuthorOfPublication07d1c222-7e64-4fc6-8209-f298a813cc88
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublication0bbf9e5a-bf3e-4645-9f2d-1e1de92915d0
relation.isAuthorOfPublication45c34df1-af1e-4065-bd94-a363edfac03a
relation.isAuthorOfPublication.latestForDiscoveryd4f139e7-cf36-415c-a82e-a9c7956ecede

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
4.pdf
Size:
1.54 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs